Literature DB >> 24805982

Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers.

F Xu1, H Zhang, Y Su, J Kong, H Yu, B Qian.   

Abstract

BACKGROUND: Lung cancer in never smokers presents predominately as adenocarcinoma and in females. MicroRNA-183 (miR-183) has various expression patterns in types of human cancers. In the present study, we evaluated the expression of miR-183-3p in female lung adenocarcinoma and adjacent noncancerous tissues and explored its relationship with clinicopathological characteristics and prognosis.
METHODS: In the present study, a hundred female nonsmoking patients who were newly diagnosed and histologically confirmed as lung adenocarcinoma at Tianjin Medical University Cancer Hospital were included. miR-183-3p expression of surgically removed NSCLC tissues and their corresponding normal lung tissues was measured by qRT-PCR assay. Associations of miR-183-3p expression with clinicopathological features were determined using the Student's t test. Log-rank test, and Cox proportional hazards model were used for survival analysis.
RESULTS: At first, miR-183-3p was up-regulated in lung cancer tissues when compared with the corresponding noncancerous lung tissues. Moreover, the expression of miR-183-3p in tumor tissue was found to be associated with lymph node metastasis (P = 0.043), clinical stage (P = 0.015), and EGFR mutation (P = 0.003). At last, high miR-183-3p expression was also associated with both poor overall survival and progression-free survival of women with lung adenocarcinoma (P = 0.005 and P = 0.010, respectively).
CONCLUSION: This study suggested that miR-183-3p expression might be involved in lung cancer pathogenesis and progression, and could be used as a potential prognostic biomarker of female lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24805982     DOI: 10.1007/s12094-014-1183-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  30 in total

1.  Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer.

Authors:  Stephen S Myatt; Jun Wang; Lara J Monteiro; Mark Christian; Ka-Kei Ho; Luca Fusi; Roberto E Dina; Jan J Brosens; Sadaf Ghaem-Maghami; Eric W-F Lam
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

2.  FOXO1 is a tumor suppressor in classical Hodgkin lymphoma.

Authors:  Linka Xie; Alexey Ushmorov; Frank Leithäuser; Hanfeng Guan; Christian Steidl; Johanna Färbinger; Christin Pelzer; Marion J Vogel; Harald J Maier; Randy D Gascoyne; Peter Möller; Thomas Wirth
Journal:  Blood       Date:  2012-02-17       Impact factor: 22.113

3.  MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology.

Authors:  Yasutoshi Yamada; Hideki Enokida; Satoko Kojima; Kazumori Kawakami; Takeshi Chiyomaru; Shuichi Tatarano; Hirofumi Yoshino; Kazuya Kawahara; Kenryu Nishiyama; Naohiko Seki; Masayuki Nakagawa
Journal:  Cancer Sci       Date:  2010-12-19       Impact factor: 6.716

4.  Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells.

Authors:  Jun Li; Shanhui Liang; Hongyan Jin; Congjian Xu; Duan Ma; Xin Lu
Journal:  Oncol Rep       Date:  2012-03-27       Impact factor: 3.906

5.  Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin.

Authors:  Junfeng Zhu; Yupeng Feng; Zunfu Ke; Zheng Yang; Junyi Zhou; Xiaorong Huang; Liantang Wang
Journal:  Am J Pathol       Date:  2012-04-21       Impact factor: 4.307

Review 6.  Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

Authors:  James A McCubrey; Linda S Steelman; C Ruth Kempf; William H Chappell; Stephen L Abrams; Franca Stivala; Graziella Malaponte; Ferdinando Nicoletti; Massimo Libra; Jörg Bäsecke; Danijela Maksimovic-Ivanic; Sanja Mijatovic; Giuseppe Montalto; Melchiorre Cervello; Lucio Cocco; Alberto M Martelli
Journal:  J Cell Physiol       Date:  2011-11       Impact factor: 6.384

7.  Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer.

Authors:  Shaosheng Wang; Xiaohong Zhao; Jie Wang; Yingmei Wen; Linjing Zhang; Dezhu Wang; Huili Chen; Qiuxia Chen; Wei Xiang
Journal:  Med Oncol       Date:  2013-08-07       Impact factor: 3.064

8.  Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study.

Authors:  Wangyu Zhu; XiaoGuang Liu; JianYing He; DongDong Chen; YanYan Hunag; Yong Kui Zhang
Journal:  BMC Cancer       Date:  2011-09-15       Impact factor: 4.430

9.  microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer.

Authors:  K Ueno; H Hirata; V Shahryari; G Deng; Y Tanaka; Z L Tabatabai; Y Hinoda; R Dahiya
Journal:  Br J Cancer       Date:  2013-03-28       Impact factor: 7.640

10.  Role of deregulated microRNAs in breast cancer progression using FFPE tissue.

Authors:  Liang Chen; Youhuai Li; Yebo Fu; Jin Peng; Meng-Hsuan Mo; Michael Stamatakos; Christine B Teal; Rachel F Brem; Alexander Stojadinovic; Michael Grinkemeyer; Timothy A McCaffrey; Yan-gao Man; Sidney W Fu
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more
  23 in total

1.  High serum miR-183 level is associated with poor responsiveness of renal cancer to natural killer cells.

Authors:  Qunmei Zhang; Wenyu Di; Yuqian Dong; Guangjian Lu; Jian Yu; Jinsong Li; Pingfa Li
Journal:  Tumour Biol       Date:  2015-06-20

2.  Clinical value and potential pathways of miR-183-5p in bladder cancer: A study based on miRNA-seq data and bioinformatics analysis.

Authors:  Jia-Min Gao; Lin-Zhen Huang; Zhi-Guang Huang; Rong-Quan He
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

3.  miR-183-5p enhances the radioresistance of colorectal cancer by directly targeting ATG5.

Authors:  Sheng Zheng; Yong-Fu Zhong; DE-Ming Tan; Yue Xu; Huai-Xiang Chen; Dan Wang
Journal:  J Biosci       Date:  2019-09       Impact factor: 1.826

4.  Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.

Authors:  Min Gyoung Pak; Chang-Hun Lee; Woo-Jeong Lee; Dong-Hoon Shin; Mee-Sook Roh
Journal:  Diagn Pathol       Date:  2015-07-12       Impact factor: 2.644

Review 5.  Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer.

Authors:  Fei Han; Jinxi He; Feng Li; Jiali Yang; Jun Wei; William C Cho; Xiaoming Liu
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

6.  The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1.

Authors:  Huifen Li; Weihua Huang; Rongcheng Luo
Journal:  Diagn Pathol       Date:  2015-07-22       Impact factor: 2.644

7.  CLCA2 as a novel immunohistochemical marker for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung.

Authors:  Kazuya Shinmura; Hisaki Igarashi; Hisami Kato; Yuichi Kawanishi; Yusuke Inoue; Satoki Nakamura; Hiroshi Ogawa; Takashi Yamashita; Akikazu Kawase; Kazuhito Funai; Haruhiko Sugimura
Journal:  Dis Markers       Date:  2014-12-07       Impact factor: 3.434

Review 8.  Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis.

Authors:  Yi Ma; A-Juan Liang; Yu-Ping Fan; Yi-Ran Huang; Xiao-Ming Zhao; Yun Sun; Xiang-Feng Chen
Journal:  Oncotarget       Date:  2016-07-05

9.  Plasma miR-19b and miR-183 as Potential Biomarkers of Lung Cancer.

Authors:  Ivan A Zaporozhchenko; Evgeny S Morozkin; Tatyana E Skvortsova; Anastasia A Ponomaryova; Elena Yu Rykova; Nadezhda V Cherdyntseva; Evgeny S Polovnikov; Oksana A Pashkovskaya; Evgeny A Pokushalov; Valentin V Vlassov; Pavel P Laktionov
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

10.  Genetic variants in regulatory regions of microRNAs are associated with lung cancer risk.

Authors:  Kaipeng Xie; Cheng Wang; Na Qin; Jianshui Yang; Meng Zhu; Juncheng Dai; Guangfu Jin; Hongbing Shen; Hongxia Ma; Zhibin Hu
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.